Clinical Trials Logo

Pulmonary Eosinophilia clinical trials

View clinical trials related to Pulmonary Eosinophilia.

Filter by:

NCT ID: NCT05091385 Not yet recruiting - Clinical trials for Asthma; Eosinophilic

Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthma

Start date: November 1, 2021
Phase:
Study type: Observational

This study is aimed at evaluation of the efficacy of mepolizumab 100 mg SC every 4 weeks in patients with severe eosinophilic asthma who have been treated for at least 12 months in several Polish allergy/asthma centres under the same protocol. Target population to be recruited has been set at 130 subjects from at least 6 asthma centers throughout the country. Data on dempgraphics and asthma status will be collected using questionnaires at 3 time-points: pre-MEPO, after 24 weeks of MEPO and after 1 year of MEPO administration (some of the outcomes will be observed every 4 weeks). Primary endpoints will include: - Asthma exacerbations measured at qualification for the treatment (in the period of previous 52 weeks) and at the 24th and 52nd week of the treatment. - Oral Corticosteroids use dose (documented at qualification for the treatment and at the 24th and 52nd week of the treatment).

NCT ID: NCT05078281 Recruiting - Clinical trials for Asthma; Eosinophilic

Patients With Severe Eosinophilic Asthma Treated With Benralizumab

Asthma
Start date: November 1, 2020
Phase:
Study type: Observational

Retrospective, multicenter, routine clinical practice study with consecutive inclusion of adult patients with severe eosinophilic asthma receiving benralizumab treatment.

NCT ID: NCT05063981 Recruiting - Asthma Clinical Trials

Treatment With Mepolizumab on Patients With Severe Refractory Eosinophilic Asthma With or Without CRSwNP.

Start date: November 25, 2021
Phase:
Study type: Observational

Patients with severe or difficult-to-treat asthma represent a small amount of total asthmatic patients, but weight on the national health system for the costs of disease management. Chronic rhinosinusitis with nasal polyposis, which the Italian severe/uncontrolled asthma registry reported with a prevalence of 30%, represents a comorbidity that significantly impact lung function and asthma control in severe asthma. Recent evidence indicates that there is a consistent heterogeneity regarding mucosal alterations present in subjects with nasal polyposis involving different pathways: inflammatory cells, remodeling, T cell activation, local IgE production, alteration induced by interactions between microorganisms and epithelial cells.

NCT ID: NCT05002621 Completed - Eosinophilic Asthma Clinical Trials

Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma

Start date: February 16, 2021
Phase:
Study type: Observational

The purpose of this study is to identify gene transcripts after initiation of mepolizumab in individuals with severe eosinophilic asthma (SEA), and to determine the composition of immune cells present in the microenvironment of individuals with SEA after initiation of mepolizumab.

NCT ID: NCT04924478 Not yet recruiting - Clinical trials for Asthma; Eosinophilic

Evaluation of Volatile Organic Compounds in Mepolizumab Therapy

EVOC4M
Start date: July 2021
Phase:
Study type: Observational

This study will recruit patients who are being prescribed Mepolizumab as part of their standard clinical care for the treatment of severe eosinophilic asthma. Over the course of their treatment, research data (questionnaires) and research samples (blood, breath and urine) will be collected in parallel to standard clinical measurements. The data and samples will be investigated to help better understand how Mepolizumab works, why it doesn't work in certain patients and why it works very well in others. This will help prescribers better identify patients that will benefit from Mepolizumab.

NCT ID: NCT04742504 Completed - Clinical trials for Asthma; Eosinophilic

Interaction Between Benralizumab and Basophils in Eosinophilic Asthma

BASEAS
Start date: September 7, 2021
Phase:
Study type: Observational

In this study, investigators want to evaluation of the impact of benralizumab (Fasenra®, Astra Zeneca) on different cell populations, including basophils and innate lymphoid cells, and several biomarkers, such as miRNAs, cadena α dek receptor pra la interleukin % (IL5Rα) and soluble IL5Rα in patients with severe eosinophilic asthma. For this, basophil and innate cells type 2 (ILC2) populations will be monitored in different point-time of treatment: 8 week (V1), 6 months (V2) and 1 year (V3) in blood and sputum samples. Also, follow-up IL5Rα expression on a cell surface of eosinophils, basophils and ILC2 from peripheral blood and sputum of patients treated with or or without benralizumab. Determination of IL5Rα levels will be performed by flow cytometry

NCT ID: NCT04710134 Completed - Clinical trials for Asthma; Eosinophilic

Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma

Start date: February 10, 2021
Phase: Phase 4
Study type: Interventional

Dose escalation of reslizumab can ameliorate sputum eosinophilia in severe asthmatics who have persistent sputum eosinophilia despite treatment with reslizumab at the standard dose.

NCT ID: NCT04680611 Recruiting - Depression Clinical Trials

Severe Asthma, MepolizumaB and Affect: SAMBA Study

SAMBA
Start date: September 9, 2021
Phase:
Study type: Observational

This is a real-life pragmatic non-randomised study to explore the impact of mepolizumab on the emotional and affective outcomes of patients with severe eosinophilic asthma and their partners. It will be conducted in two quantitative stages (Phases 1 and 2) with an additional third qualitative component (Phase 3).

NCT ID: NCT04674137 Completed - Bronchial Asthma Clinical Trials

XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma

Start date: December 16, 2020
Phase: Phase 2
Study type: Interventional

A multicenter, double-blind, randomized, pilot study in parallel groups to assess the efficacy and safety of XC8 at a dose of 100 mg versus placebo over a 12-week treatment period in non-smoking patients with a confirmed bronchial asthma (BA) and the eosinophil blood level 2 times within 1 week interval of ≥ 300 cells/μl. Study design was developed by Chemlmmune Therapeutics LLC, Russia in cooperation with Eurrus Biotech GmbH, Austria.

NCT ID: NCT04671446 Recruiting - Clinical trials for Eosinophilic Esophagitis

Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma

IDEA
Start date: December 10, 2020
Phase:
Study type: Observational

In this project the investigators will look for auto-antibodies to relevant proteins both in native form and importantly in post-translationally modified forms. Potential modified auto-antigens are eosinophil proteins (analogous to the cytoplasmic neutrophil proteins identified in vasculitides such as Granulomatosis with Polyangiitis (formerly known as Wegener's granulomatosis) and alternatively structural proteins such as collagen V. As well as advancing the understanding of asthma pathology, identifying a serum auto-antibody that could then be used as a clinical blood test, analogous to anti-cyclic citrullinated peptide (CCP) antibodies in rheumatoid arthritis, may revolutionise diagnosis of severe eosinophilic asthma and Eosinophilic Granulomatosis with Polyangiitis (EGPA). There is a considerable burden of undiagnosed severe eosinophilic asthma in part due to difficulties in definitive diagnosis and a diagnostic blood test would help diagnose these patients, allowing them to receive necessary treatment.